Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. director equity compensation filing: Director Roy D. Baynes received 70 shares of Natera common stock on 01/30/2026, reported as an acquisition under code "A". These shares were issued as Restricted Stock Units in lieu of a quarterly board retainer of $16,875.
The RSUs were fully vested at the time of issuance, and each RSU represents a right to receive one share of Natera common stock. Following this award, Baynes beneficially owns 18,429 shares of Natera common stock, held in direct ownership.
An affiliate of the issuer, Michael Brophy, filed a Form 144 notice to sell 5,671 shares of common stock through Morgan Stanley Smith Barney on NASDAQ. These shares were acquired as restricted stock units on 09/28/2025, when payment was recorded as non-cash (N/A).
The filing notes that 138,014,465 common shares were outstanding and lists several sales during the prior three months, including transactions under a Rule 10b5-1 sales plan and direct sales, with individual trades as large as 36,573 and 23,948 shares of common stock.
An insider associated with ticker NTRA has filed a Form 144 indicating an intent to sell up to 85,299 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $19,679,798.82 on the NASDAQ. The notice shows these shares were acquired as restricted stock and performance shares from the issuer in 2022 and 2026. It also lists multiple prior sales of common shares over the past three months by Steven L. Chapman, each with specified dates, share amounts, and gross proceeds, as required under Rule 144 disclosure rules.
Natera insider Solomon Moshkevich has filed to sell 3,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on NASDAQ, has an aggregate market value of $694,309.20. The approximate sale date indicated is February 2, 2026.
The 3,000 shares were acquired on January 14, 2026 as performance shares from the issuer. The notice also lists multiple prior sales of Natera common stock over the past three months, including 23,205 shares sold on January 20, 2026 for $5,447,104.57. Natera had 138,014,465 shares of common stock outstanding.
Natera, Inc. CEO and president Steven Leonard Chapman reported two small insider sales of common stock that were tied to restricted stock unit (RSU) vesting and related tax obligations. On January 27, 2026, he sold 2,322 shares at $240.5313, leaving 216,828 shares directly owned. On January 28, 2026, he sold 3,648 shares at $237.6624, leaving 213,180 shares directly owned. Both sales were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions and were made to cover tax withholding and remittance obligations from RSU vesting.
Natera, Inc.’s chief financial officer Michael Burkes Brophy reported multiple sales of common stock on January 27–29, 2026. He sold blocks of 784, 1,237, 1,176, 991 and 876 shares at prices around $240–$230 per share. Footnotes state that part of the sales satisfied tax withholding obligations tied to vesting restricted stock units and relied on written instructions intended to qualify under Rule 10b5-1(c). Other sales were executed under a Rule 10b5-1 trading plan adopted on June 9, 2025 and modified on September 10, 2025. After these transactions, he directly held 59,059 common shares.
Natera, Inc. director and co-founder Sheena Jonathan reported small stock sales mainly to cover taxes on vesting RSUs. On January 27, 2026, she sold 291 shares of common stock at $240.5313 per share. On January 28, 2026, she sold an additional 191 shares at $237.6624 per share. After these transactions, she directly owned 263,596 shares of Natera common stock and indirectly held 21,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust. The filing explains that both sales were executed to satisfy tax withholding and remittance obligations related to RSU vesting and were made under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold small blocks of common stock to cover taxes on restricted stock unit (RSU) vesting. On January 27, 2026, he sold 886 shares at $240.5313 per share. On January 28, 2026, he sold an additional 1,000 shares at $237.6624 per share.
Both sales were made under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) and were specifically to satisfy tax withholding and remittance obligations tied to previously granted RSUs. After these transactions, Rabinowitz directly owned 225,147 shares of Natera common stock.
Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, reported small insider sales of common stock tied to RSU vesting. On January 27, 2026, he sold 1,013 shares at $240.5313, and on January 28, 2026 he sold 1,200 shares at $237.6624.
The filing states both sales were made to satisfy tax withholding and remittance obligations from restricted stock unit vesting, under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, he directly owns 142,486 shares of Natera common stock.
Natera, Inc. officer John Fesko reported small automatic sales of common stock tied to restricted stock unit vesting. On January 27, 2026, he sold 784 shares at $240.5313 each, and on January 28, 2026 he sold 928 shares at $237.6624 each. The transactions were made to satisfy tax withholding and remittance obligations under pre-set instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these sales, he beneficially owned 175,540 shares of Natera common stock directly.